S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

$72.52
-6.35 (-8.05%)
(As of 04/18/2024 ET)
Today's Range
$72.50
$78.70
50-Day Range
$68.64
$89.20
52-Week Range
$49.24
$94.57
Volume
131,218 shs
Average Volume
159,074 shs
Market Capitalization
$1.28 billion
P/E Ratio
26.37
Dividend Yield
N/A
Price Target
$116.33

Ligand Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.4% Upside
$116.33 Price Target
Short Interest
Healthy
4.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
0.84mentions of Ligand Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$153,034 Sold Last Quarter
Proj. Earnings Growth
16.72%
From $3.41 to $3.98 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.93 out of 5 stars

Medical Sector

12th out of 918 stocks

Pharmaceutical Preparations Industry

3rd out of 402 stocks

LGND stock logo

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

LGND Stock Price History

LGND Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
7 Small-Cap Stocks for the Thinking Speculator
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
LGND Apr 2024 70.000 put
LGND Apr 2024 110.000 call
Ligand Pharmaceuticals Incorporated (LGND)
LGND Aug 2024 110.000 call
LGND Apr 2024 90.000 call
Ligand Pharmaceuticals's Earnings: A Preview
LGND Mar 2024 65.000 put
See More Headlines
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$116.33
High Stock Price Target
$144.00
Low Stock Price Target
$95.00
Potential Upside/Downside
+60.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$52.15 million
Pretax Margin
48.48%

Debt

Sales & Book Value

Annual Sales
$131.31 million
Cash Flow
$4.54 per share
Book Value
$40.39 per share

Miscellaneous

Free Float
15,864,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
1.01
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Todd C. Davis Ph.D. (Age 63)
    CEO & Director
    Comp: $743.49k
  • Mr. Matthew E. Korenberg (Age 49)
    President & COO
    Comp: $760.99k
  • Mr. Octavio Espinoza (Age 53)
    Chief Financial Officer
    Comp: $457.19k
  • Mr. Andrew T. Reardon J.D. (Age 49)
    Chief Legal Officer & Secretary
    Comp: $480.16k
  • Mr. Paul J. Hadden
    Senior Vice President of Investments & Business Development
  • Simon Latimer
    Head of Investor Relations
  • Mr. Todd Pettingill
    Director of Corporate Development
  • Ms. Audrey Warfield-Graham
    Chief People Officer
  • Dr. Keith Marschke
    Senior Vice President of Biology & Scientific Affairs
  • Dr. Vincent D. Antle (Age 55)
    Senior Vice President of Technical Operations & QA - Capitsol

LGND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price target for 2024?

3 analysts have issued twelve-month price targets for Ligand Pharmaceuticals' stock. Their LGND share price targets range from $95.00 to $144.00. On average, they anticipate the company's share price to reach $116.33 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price.
View analysts price targets for LGND
or view top-rated stocks among Wall Street analysts.

How have LGND shares performed in 2024?

Ligand Pharmaceuticals' stock was trading at $71.42 on January 1st, 2024. Since then, LGND shares have increased by 1.5% and is now trading at $72.52.
View the best growth stocks for 2024 here
.

Are investors shorting Ligand Pharmaceuticals?

Ligand Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 672,100 shares, a decline of 23.3% from the March 15th total of 876,300 shares. Based on an average trading volume of 162,300 shares, the days-to-cover ratio is currently 4.1 days. Currently, 4.1% of the company's shares are sold short.
View Ligand Pharmaceuticals' Short Interest
.

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LGND earnings forecast
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.55. The biotechnology company earned $28.10 million during the quarter, compared to analyst estimates of $24.54 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 11.98% and a net margin of 37.80%.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY24 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $4.25 to $4.75 for the period, compared to the consensus EPS estimate of $4.28. The company issued revenue guidance of $130 million to $142 million, compared to the consensus revenue estimate of $137.66 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.48%), BTC Capital Management Inc. (0.03%) and M&R Capital Management Inc. (0.01%). Insiders that own company stock include Andrew Reardon, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends
.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LGND) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners